ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 271 filers reported holding ACCELERON PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $7,592,000 | -7.4% | 60,500 | 0.0% | 2.00% | -7.6% |
| Q1 2021 | $8,199,000 | -9.5% | 60,500 | -14.8% | 2.17% | -12.4% |
| Q4 2020 | $9,063,000 | +13.6% | 71,000 | 0.0% | 2.48% | -3.9% |
| Q3 2020 | $7,978,000 | +361.4% | 71,000 | +294.4% | 2.58% | +347.8% |
| Q2 2020 | $1,729,000 | +6.9% | 18,000 | 0.0% | 0.58% | -22.0% |
| Q1 2020 | $1,617,000 | -46.5% | 18,000 | -68.4% | 0.74% | -32.3% |
| Q4 2019 | $3,021,000 | +155.2% | 57,000 | +90.0% | 1.09% | +98.9% |
| Q3 2019 | $1,184,000 | -4.0% | 30,000 | 0.0% | 0.55% | +19.7% |
| Q2 2019 | $1,233,000 | -11.7% | 30,000 | 0.0% | 0.46% | -11.4% |
| Q1 2019 | $1,396,000 | -75.7% | 30,000 | -80.5% | 0.52% | -76.9% |
| Q3 2017 | $5,749,000 | +6.5% | 153,633 | -13.5% | 2.24% | +9.1% |
| Q2 2017 | $5,397,000 | +19.6% | 177,643 | +4.1% | 2.05% | +18.7% |
| Q1 2017 | $4,514,000 | +850.3% | 170,606 | +816.9% | 1.73% | +707.5% |
| Q4 2016 | $475,000 | – | 18,606 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |